Page 57 - 2019_11 Resto del Mondo-web

Guidelines for HHV-6 infections
pesvirus-6 replication on active cytome- galovirus infection after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(5):653-661.
68. Wang FZ, Larsson K, Linde A, Ljungman P. Human herpesvirus 6 infection and cytomegalovirus-specific lymphoprolifera- tive responses in allogeneic stem cell trans- plant recipients. Bone Marrow Transplant. 2002;30(8):521-526.
69. Smith AP, Paolucci C, Di Lullo G, Burastero SE, Santoro F, Lusso P. Viral replication-inde- pendent blockade of dendritic cell maturation and interleukin-12 production by human her- pesvirus 6. J Virol. 2005;79(5): 2807-2813.
70. Lusso P. HHV-6 and the immune system: mechanisms of immunomodulation and viral escape. J Clin Virol. 2006; 37 Suppl 1:S4-10.
71. Admiraal R, de Koning CCH, Lindemans CA, et al. Viral reactivations and associated outcomes in the context of immune recon- stitution after pediatric hematopoietic cell transplantation. J Allergy Clin Immunol. 2017;140(6):1643-1650.
72. Phan TL, Carlin K, Ljungman P, et al. Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft-versus-Host Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2018;24(11):2324-2336.
73. de Pagter PJ, Schuurman R, Visscher H, et al. Human herpes virus 6 plasma DNA positiv- ity after hematopoietic stem cell transplanta- tion in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant. 2008;14(7):831-839.
74. Hill JA, Mayer BT, Xie H, et al. Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplan- tation. Clin Infect Dis. 2018;66(3):368-375.
75. Prichard MN, Whitley RJ. The development of new therapies for human herpesvirus 6. Curr Opin Virol. 201;9:148-153.
76. Manichanh C, Olivier-Aubron C, Lagarde JP, et al. Selection of the same mutation in the U69 protein kinase gene of human her- pesvirus-6 after prolonged exposure to gan- ciclovir in vitro and in vivo. J Gen Virol. 2001;82(Pt 11):2767-2776.
77. Isegawa Y, Hara J, Amo K, et al. Human her- pesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient. J Clin Virol. 2009;44(1):15-19.
78. Baldwin K. Ganciclovir-resistant human her- pesvirus-6 encephalitis in a liver transplant patient: a case report. J Neurovirol. 2011;17 (2):193-195.
79. Piret J, Boivin G. Antiviral drug resistance in herpesviruses other than cytomegalovirus. Rev Med Virol. 2014;24(3):186-218.
80. Bounaadja L, Piret J, Goyette N, Boivin G. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. J Clin Virol. 2013;58(1): 279-282.
81. Williams-Aziz SL, Hartline CB, Harden EA, et al. Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replica- tion of herpesviruses in vitro. Antimicrob Agents Chemother. 2005;49(9):3724-3733.
82. Marty FM, Winston DJ, Chemaly RF, et al. A Randomized, Double-Blind, Placebo- Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019;25(2):369-381.
83. Wire MB, Morrison M, Anderson M, Arumugham T, Dunn J, Naderer O. Pharmokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects. Open Forum Infect Dis. 2017;4(Suppl 1):S311.
84. Becerra A, Gibson L, Stern LJ, Calvo-Calle JM. Immune response to HHV-6 and impli- cations for immunotherapy. Curr Opin Virol. 2014;9:154-161.
85. Tzannou I, Papadopoulou A, Naik S, et al. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017;35(31):3547-3557.
86. Ishiyama K, Katagiri T, Ohata K, et al. Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation. Transpl Infect Dis. 2012;14 (1):33-39.
87. Ogata M, Satou T, Inoue Y, et al. Foscarnet against human herpesvirus (HHV)-6 reacti- vation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis. Bone Marrow Transplant. 2013;48(2):257- 264.
88. Ogata M, Takano K, Moriuchi Y, et al. Effects of Prophylactic Foscarnet on Human Herpesvirus-6 Reactivation and Encephalitis in Cord Blood Transplant Recipients: A Prospective Multicenter Trial with an Historical Control Group. Biol Blood Marrow Transplant. 2018;24(6):1264-1273.
89. Ogata M, Satou T, Kawano R, et al. Plasma HHV-6 viral load-guided preemptive thera-
py against HHV-6 encephalopathy after allo- geneic stem cell transplantation: a prospec- tive evaluation. Bone Marrow Transplant. 2008;41(3):279-285.
90. Ishiyama K, Katagiri T, Hoshino T, Yoshida T, Yamaguchi M, Nakao S. Preemptive ther- apy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT. Bone Marrow Transplant. 2011;46(6):863-869.
91. Zerr DM, Gupta D, Huang ML, Carter R, Corey L. Effect of antivirals on human her- pesvirus 6 replication in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(3):309-317.
92. Ljungman P, Dahl H, Xu YH, Larsson K, Brytting M, Linde A. Effectiveness of ganci- clovir against human herpesvirus-6 excreted in saliva in stem cell transplant recipients. Bone Marrow Transplant 2007; 39(8):497- 499.
93. Vu T, Carrum G, Hutton G, Heslop HE, Brenner MK, Kamble R. Human her- pesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39(11):705- 709.
94. Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 2008;42(4):227-240.
95. Schmidt-Hieber M, Schwender J, Heinz WJ, et al. Viral encephalitis after allogeneic stem cell transplantation: a rare complication with distinct characteristics of different causative agents. Haematologica. 2011;96(1):142-149.
96. Denes E, Magy L, Pradeau K, Alain S, Weinbreck P, Ranger-Rogez S. Successful treatment of human herpesvirus 6 encephalomyelitis in immunocompetent patient. Emerg Infect Dis. 2004;10(4):729- 731.
97. Pohlmann C, Schetelig J, Reuner U, et al. Cidofovir and foscarnet for treatment of human herpesvirus 6 encephalitis in a neu- tropenic stem cell transplant recipient. Clin Infect Dis. 2007;44(12):e118-e120.
98. Hill JA, Zerr DM. Human herpesvirus 6A, 6B, 7 and 8 infections After Hematopoietic Stem Cell Transplantation. In: Ljungman P, Snydman D, Boeckh M, editors. Switzerland: Springer International. 2016. pp.547-562.
99. Hill JA, Zerr DM. Roseoloviruses in trans- plant recipients: clinical consequences and prospects for treatment and prevention tri- als. Curr Opin Virol. 2014;9:53-60.
haematologica | 2019; 104(11)
2163